Biotech M&A: Unlocking Value
Big pharma is on the verge of losing about $170B in patents and exclusivity (between now and 2030). This means those big companies are all looking for the next breakthrough (read: outsourcing innovation). Get ready to see a ton of biotech and healthcare M&A activity!
Biotech fund portfolio manager and chemical biologist, Mark Charest knows how to unlock value in this environment. In this video, he explains what to look for: